STAGE II NONSEMINOMATOUS TESTIS CANCER: THE ROLES OF PRIMARY AND ADJUVANT CHEMOTHERAPY
- 1 August 1998
- journal article
- review article
- Published by Elsevier in Urologic Clinics of North America
- Vol. 25 (3) , 451-459
- https://doi.org/10.1016/s0094-0143(05)70034-3
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- LONG-TERM SIDE EFFECTS OF TREATMENT FOR TESTIS CANCERUrologic Clinics of North America, 1998
- Immunohistochemical Expression of Ki-67 to Predict Lymph Node Involvement in Clinical Stage I Nonseminomatous Germ Cell TumorsJournal of Urology, 1997
- Testicular Germ-Cell CancerNew England Journal of Medicine, 1997
- Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.Journal of Clinical Oncology, 1996
- Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumorsJournal of Surgical Oncology, 1996
- The Role of Retroperitoneal Lymphadenectomy in Clinical Stage B Testis Cancer: The Indiana University Experience (1965 to 1989)Journal of Urology, 1995
- Immediate Adjuvant Chemotherapy versus Observation with Treatment at Relapse in Pathological Stage II Testicular CancerNew England Journal of Medicine, 1987
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideNew England Journal of Medicine, 1987
- Adjuvant chemotherapy in nonseminomatous testicular tumour stage IIInternational Journal of Andrology, 1987
- Clinical Stage II Non‐seminomatous Germ Cell Testicular Tumours. Results of Management by Primary ChemotherapyBritish Journal of Urology, 1985